Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Rehabilitation Group Significantly Reduces Fatigue-Related Stress

August 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 8
Volume 10
Issue 8

TAMPA, Florida-A rehabilitation group program-Energy for Living With Cancer-has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

TAMPA, Florida—A rehabilitation group program—Energy for Living With Cancer—has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

The Energy for Living With Cancer program is a structured rehabilitation intervention designed to educate patients about cancer-related fatigue and to provide support and sharing among participants. Patients meet for 90 minutes once a week for 8 weeks.

The education component covers topics such as risk factors for fatigue, how fatigue affects daily living, and fatigue management strategies. In the sharing and support component, patients relay their experiences, share coping techniques, and provide emotional support for one another.

To test the effectiveness of the program, Dr. Holley conducted a prospective pre/post-test study involving 20 program participants. The mean age of the participants was 63.6 (range, 38 to 86). Six different types of cancer were represented, and 15 of the patients were receiving cancer therapy at the time.

At the start of the program, study participants completed the Cancer-Related Fatigue Distress Scale, the Center for Epidemiological Studies—Depression form, and the Functional Living Index—Cancer scale. Upon study completion, participants re-took the tests and completed a program rating form.

Program rating results indicated a high degree of patient satisfaction with the program. On a scale of 0 to 10, the mean rating in the program evaluation was 9.8. Patients indicated that the educational topics were relevant and beneficial and that the 8-week fatigue-management intervention provided much-needed information and emotional support.

Moreover, post-program test results showed significant improvements in fatigue-related distress and quality of life. Fatigue distress scores decreased from a mean of 192.95 to 145.45, and quality-of-life scores increased from 98.65 to 145.45—nearly a 50% improvement. Depression scores decreased from 24.05 to 21.0, but this difference was not statistically significant.

Dr. Holley said that these preliminary findings indicate that the Energy for Living With Cancer program is appropriate and beneficial for cancer patients experiencing fatigue, even for those who are quite debilitated.

Articles in this issue

Amifostine Can Reduce Xerostomia, Loss of Taste, Fibrosis, and Pain
Three-Dimensional Conformal Radiation Therapy Reduces Rectal Damage in Prostate Cancer Treatment
Can Concurrent Amifostine and 5-FU Permit Delivery of Higher Boost Doses of Radiation?
Preventing Severe Esophagitis Critical in Chemoradiotherapy for Lung Cancer
Upcoming Trial to Test Ability of Amifostine to Reduce Radiation-Induced Hypothyroidism
Amifostine Offers Little Advantage in Small Trial of Twice-Daily Radiation Plus Chemotherapy
Subcutaneous Amifostine Provides Protection Against Radiation-Induced Acute Xerostomia
Study to Test Amifostine in Cervical Cancer Patients Treated With Combined-Modality Therapy
Radioprotectants May Extend Use of Combined Chemotherapy and Radiation
Amifostine Ameliorates Pneumonitis and Esophagitis During Radiochemotherapy
Potentially Useful Predictors of Risk for Developing Postradiation Pneumonitis
Amifostine Trial Represents First FDA Approval of Treatment Interacting With Radiation
Amifostine Reduces Side Effects During Treatment for Advanced Lung Cancer
Intrarectal Amifostine Prevents Late Rectal Complications of Radiotherapy for Prostate Cancer
Experts Consider Statistical Issues in Designing Studies of Toxicity Modifiers
Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content
Advertisement

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Roman Fabbricatore
November 5th 2025
Article

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC

Caroline Seymour
November 4th 2025
Article

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Related Content
Advertisement

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Roman Fabbricatore
November 5th 2025
Article

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC

Caroline Seymour
November 4th 2025
Article

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.